Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05870163

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Friedrichshafen GmbH, Friedrichshafen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide informed consent and to participate in the registry study,
  • Patient's age ≥ 18 years or according to local legal age of adulthood if older,
  • Documented GERD present for > 6 months,
  • Patient has a 24-hour pH monitoring proven GERD with pH and/or impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be <4 for >4.5% of time during a 24-hour monitoring and/or total reflux episodes of acid >55 or weakly acid >26 for >5 seconds at 5 cm above LES)
  • Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator.

Exclusion criteria

  • Presence of para-esophageal hernia or sliding hernia > 3 centimeters,
  • Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed,
  • History of bariatric surgery wherein the stomach fundus has been extirpated,
  • Female patients who are pregnant or nursing,
  • Known sensitivity or allergies to silicone materials,
  • Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU);
  • Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement).

Treatment and study plan

RefluxStop implantation

Device

Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use

Nissen fundoplication

Procedure

Standard of care Nissen fundoplication surgery

Primary outcomes

  1. Primary safety endpoint

    Time frame: 6 months

    Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs)

  2. Primary performance endpoint

    Time frame: 6 months

    Assessment of GERD symptoms, measured by GERD Health-Related Quality of Life (HRQL) score (questions 1-10).

    (An answer of zero means no symptoms)

Secondary outcomes

  1. Secondary safety endpoint

    Time frame: 3 and 6 months and annually up to 5 years

    Incidence of Serious Adverse Device Effects (SADEs), Serious Adverse Events (SAEs) and Device Deficiencies (DDs) at 3 months and annually up to 5 years.

    Plus Incidence of Adverse Device Effects (ADEs) and procedure related or unknown Adverse Events (AEs) at 3 and 6 months and annually up to 5 years

  2. Secondary performance endpoints

    Time frame: 3 months and annually up to 5 years

    Assessment of GERD symptoms, assessed by GERD-HRQL score (questions 1-10)

  3. Secondary performance endpoints: RefluxStop device position

    Time frame: 6 months

    Location and function of the device evaluated by a simplified contrast swallow x-ray with overview pictures of device

  4. Secondary performance endpoints: hernia assessment

    Time frame: 6 months

    Location of baseline hernia or any new hernia by a simplified contrast swallow x-ray picture

  5. Secondary performance endpoints: pH monitoring

    Time frame: 6 months

    Reduction or normalisation from baseline of the total acid (pH<4) exposure time during 24-hour pH monitoring

Other outcomes

  1. Exploratory endpoints: Patient Reported Outcomes - Quality of life questionnaire

    Time frame: 3 and 6 months and annually up to 5 years

    EQ-5D (Euro Quality of life-5 Dimension) questionnaire: measure of quality of life with one question for each of the five dimensions that are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, the patients assess if they have no problem, slight, moderate, severe or extreme problems.

  2. Exploratory endpoints: Patient Reported Outcomes - Work related questionnaire

    Time frame: 3 and 6 months and annually up to 5 years

    WPAI (work related productivity gains): 5 questions to assess how health problems effect the patient work Score 0 to 10. Zero meaning health problems have no effect on work

  3. Exploratory endpoints: Health economic outcomes - Visit to General Practitioner

    Time frame: 3 and 6 months and annually up to 5 years

    Evaluation of number of visit to the General Practitioner

  4. Exploratory endpoints: Health economic outcomes - PPI treatment use

    Time frame: 3 and 6 months and annually up to 5 years

    Counting of the number of patients using PPI (Proton Pump Inhibitors)

  5. Exploratory endpoints: Health economic outcomes - Re-admission to hospital

    Time frame: 3 and 6 months and annually up to 5 years

    Counting of the number of re-admission to hospital due to complications

  6. Exploratory endpoints: Health economic outcomes - Procedure costs

    Time frame: 3 and 6 months and annually up to 5 years

    Evaluation of the costs related to the study procedure and the length of hospital stay

Study contacts

Contact information is provided by the study sponsor or research team.

Souheila Moutiq

CONTACT

[email protected]

+41 78 249 77 28

Sponsors and collaborators

Lead sponsor

Implantica CE Reflux Ltd.

Industry

Registry information

Official study title

A Post-market Registry Study to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice

Important dates

Study start
2023
Primary completion
2025
Study completion
2029
First posted
May 23, 2023
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.